Sinopharm (01099.HK): Zhao Bingxiang has been appointed as the Chairman of the Nomination Committee of the Board of Directors and other positions.

On September 15th, Guolonghui announced that Sinopharm (01099.HK) has appointed Zhao Bingxiang as a non-executive director, and Lian Wanyong as an executive director. The company's board of directors announced that non-executive director Zhao Bingxiang has been appointed as chairman of the board nomination committee, chairman of the board strategy and investment committee, and member of the board legal compliance and environmental, social and governance committee. In addition, executive director Lian Wanyong has been appointed as a member of the board strategy and investment committee and the board legal compliance and environmental, social and governance committee, effective from September 14, 2024.

Gelonghui FinanceSep 15 06:12 ET

Sinopharm Unveils Current Board Structure and Roles

TipRanksSep 13 05:41 ET

Sinopharm Group EGM: Directors Approved, Auditors Appointed

TipRanksSep 13 05:12 ET

Sinopharm's early trading rose more than 4%, the company's pharmaceutical distribution business may show steady growth in the second half of the year.

Sinopharm (01099) rose 4.28% in early trading, now at HKD 17.06, with a turnover of HKD 84.975 million. Sinopharm previously released its mid-year performance, achieving revenue of CNY 294.727 billion in the first half of the year, a year-on-year decrease of 2.07%, and a net income attributable to the parent company of CNY 3.704 billion, a year-on-year decrease of 9.76%.

新浪港股Sep 12 22:43 ET

Hong Kong stocks rise | Sinopharm (01099) rose more than 5% in early trading, pharmaceutical distribution business is expected to grow steadily in the second half of the year, and medical device distribution business is expected to improve compared to the

Sinopharm (01099) rose more than 5% in early trading. As of the time of writing, it has increased by 4.4%, reaching HKD 17.08 with a turnover of HKD 80.6915 million.

Zhitong FinanceSep 12 22:30 ET

China Securities Co., Ltd. maintains a "buy" rating on Sinopharm (01099), and expects the medical device distribution business to improve compared to the previous year in the second half of the year.

China Securities Co., Ltd. released a research report stating that sinopharm (01099) has released its 2024 semi-annual performance report. In the first half of 2024, the company achieved revenue of 294.727 billion yuan, a year-on-year decrease of 2.07%, and achieved a net income of 3.704 billion yuan attributable to the parent, a year-on-year decrease of 9.76%. The performance was lower than expected, mainly due to pressure on the medical device distribution business. The bank pointed out that in the second half of the year, the impact of compliant sales in hospitals is expected to stabilize, the pharmaceutical distribution business may maintain steady growth, and the replacement of medical devices is expected to release incremental growth. The distribution business of medical devices is expected to improve on a month-on-month basis, with the company continuing to focus on building.

金吾財訊Sep 11 03:16 ET